SG11202112541RA - Separation moieties and methods and use thereof - Google Patents

Separation moieties and methods and use thereof

Info

Publication number
SG11202112541RA
SG11202112541RA SG11202112541RA SG11202112541RA SG11202112541RA SG 11202112541R A SG11202112541R A SG 11202112541RA SG 11202112541R A SG11202112541R A SG 11202112541RA SG 11202112541R A SG11202112541R A SG 11202112541RA SG 11202112541R A SG11202112541R A SG 11202112541RA
Authority
SG
Singapore
Prior art keywords
methods
separation moieties
moieties
separation
Prior art date
Application number
SG11202112541RA
Inventor
William Winston
Luke Evnin
Vinay Bhaskar
Giselle Knudsen
Daniel Hicklin
Cynthia Seidel-Dugan
Garcia Jose Andres Salmeron
Heather Brodkin
Original Assignee
Werewolf Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werewolf Therapeutics Inc filed Critical Werewolf Therapeutics Inc
Publication of SG11202112541RA publication Critical patent/SG11202112541RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22015—Cathepsin L (3.4.22.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
SG11202112541RA 2019-05-14 2020-05-14 Separation moieties and methods and use thereof SG11202112541RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847914P 2019-05-14 2019-05-14
US201962938786P 2019-11-21 2019-11-21
PCT/US2020/032988 WO2020232305A1 (en) 2019-05-14 2020-05-14 Separation moieties and methods and use thereof

Publications (1)

Publication Number Publication Date
SG11202112541RA true SG11202112541RA (en) 2021-12-30

Family

ID=73289342

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112541RA SG11202112541RA (en) 2019-05-14 2020-05-14 Separation moieties and methods and use thereof

Country Status (12)

Country Link
US (3) US20210115102A1 (en)
EP (1) EP3969035A4 (en)
JP (1) JP2022532217A (en)
KR (1) KR20220023988A (en)
CN (1) CN114450022A (en)
AU (1) AU2020275877A1 (en)
BR (1) BR112021022666A2 (en)
CA (1) CA3137512A1 (en)
IL (1) IL287977A (en)
MX (1) MX2021013766A (en)
SG (1) SG11202112541RA (en)
WO (1) WO2020232305A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022502088A (en) 2018-09-27 2022-01-11 エクシリオ デベロップメント， インコーポレイテッド Masked cytokine polypeptide
JP2023503258A (en) * 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド Activatable cytokine polypeptides and methods of use thereof
CN110862459A (en) * 2019-11-18 2020-03-06 温州医科大学 HPV16E7 affibody-loaded granzyme B affoxin targeting molecule and application thereof
MX2022012592A (en) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Activatable cytokine constructs and related compositions and methods.
JP2023550880A (en) 2020-10-26 2023-12-06 サイチューン ファーマ IL-2/IL-15Rβγ agonist for treating non-melanoma skin cancer
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
IL303853A (en) 2021-01-29 2023-08-01 Allogene Therapeutics Inc KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
CA3211924A1 (en) 2021-03-16 2022-09-22 Sayantan Mitra Masked activatable cytokine constructs and related compositions and methods
WO2023150735A2 (en) * 2022-02-04 2023-08-10 The Board Of Trustees Of The Leland Stanford Junior University Surrogate cytokine polypeptides
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
EP0547163B1 (en) 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19701141C1 (en) 1997-01-16 1998-04-09 Hoechst Ag Gene construct for treatment of disease involving protease, particularly tumours and inflammation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
DE69830315T2 (en) 1997-06-24 2006-02-02 Genentech Inc., San Francisco GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
IT1306736B1 (en) 1999-10-29 2001-10-02 Benito Salmi CONTAINMENT AND DISTRIBUTION DEVICE FOR BALLS FOR ALVOLO SHOOTS.
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EP1276849A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
DE10045592A1 (en) 2000-09-15 2002-03-28 Klaus Pfizenmaier An antibody-TNF-TNF inhibitor fusion protein (TNF selectokine) as a target-specific procytokine for tumor therapy
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
JP3523245B1 (en) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド Transgenic chromosome-introduced rodents for the production of human antibodies
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
FI117667B (en) * 2001-07-05 2007-01-15 Univ Zuerich A pharmaceutical composition suitable for use in orthopedics and dentistry
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
ES2326964T3 (en) 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS.
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
ES2425013T3 (en) * 2002-06-12 2013-10-10 Symphony Evolution, Inc. Human ADAM-10 inhibitors
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
CN1703423A (en) 2002-10-14 2005-11-30 豪夫迈－罗氏公司 Antagonists il-15
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524036A (en) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． Single domain antibodies targeting tumor necrosis factor alpha and uses thereof
DE60332957D1 (en) 2002-12-16 2010-07-22 Genentech Inc IMMUNOGLOBULIN VARIANTS AND ITS USES
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004090135A2 (en) 2003-04-09 2004-10-21 Asterion Limited Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
KR101520209B1 (en) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Medicament containing antibody composition
BRPI0507026A (en) 2004-02-09 2007-04-17 Human Genome Sciences Inc albumin fusion proteins
AU2004101073B4 (en) 2004-12-21 2005-08-18 Kerry William O'Hanlon A Beverage Container Holder
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006110728A2 (en) 2005-04-12 2006-10-19 The Uab Research Foundation Immunogenic cmv tegument aggregates
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US20110252501A1 (en) * 2006-08-17 2011-10-13 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
EP2068905A4 (en) 2006-09-14 2009-12-30 Human Genome Sciences Inc Albumin fusion proteins
ATE554859T1 (en) 2007-05-24 2012-05-15 Univ California INTEGRATED FLUIDIC DEVICES WITH MAGNETIC SORTING
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
JP2011512134A (en) 2008-02-19 2011-04-21 アステリオン・リミテッド Modified linker
US8575102B2 (en) 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
RU2636046C2 (en) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
BRPI1011384A2 (en) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc proproteins and their methods of use
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior Cytokine compositions and methods of use thereof
US20130064788A1 (en) 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
WO2012054929A2 (en) 2010-10-22 2012-04-26 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
LT2637694T (en) 2010-11-12 2021-05-25 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
IN2015KN00329A (en) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
JP6605957B2 (en) 2013-01-04 2019-11-13 シトムクス セラピューティクス，インコーポレイティド Compositions and methods for detecting protease activity in biological systems
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US9517276B2 (en) 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
HRP20220553T1 (en) 2013-07-25 2022-06-10 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA3214529A1 (en) 2013-09-25 2015-04-02 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
AU2015210862B2 (en) 2014-01-31 2020-04-23 Cytomx Therapeutics, Inc Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
IL247320B (en) 2014-02-21 2022-09-01 Nektar Therapeutics Use of il -2r beta – selective agonists in combination with anti ctla – 4 or pd - 1 antibodies for treating cancer
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3292149B1 (en) 2015-05-04 2021-12-01 CytomX Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
CA2984948A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
WO2016200645A1 (en) 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
KR20180040138A (en) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them
MA43816A (en) 2016-03-08 2018-11-28 Maverick Therapeutics Inc INDUCTIBLE BINDING PROTEINS AND METHODS OF USE
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
AU2017342559B2 (en) 2016-10-14 2022-03-24 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
PE20191131A1 (en) 2016-11-03 2019-09-02 Bristol Myers Squibb Co ACTIVABLE CYTOTOXIC T LYMPHOCYTE 4 ANTI ANTIGEN (CTLA-4) ANTIBODIES AND THEIR USES
WO2018136725A1 (en) 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110366421A (en) 2017-03-01 2019-10-22 尼克塔治疗公司 Using Interleukin 2 Receptor α, the combined tumor immunotherapy treatment method of beta selective agonists and adoptive cell transfer therapy
AU2018231127A1 (en) 2017-03-09 2019-09-19 Cytomx Therapeutics, Inc. CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
KR20190141760A (en) 2017-05-02 2019-12-24 넥타르 테라퓨틱스 Immunotherapy Tumor Treatment Methods
EP3619234A4 (en) * 2017-05-03 2021-05-26 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
MX2019013621A (en) 2017-05-15 2020-01-13 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods.
BR112019025188A2 (en) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
EP3641829A4 (en) 2017-06-20 2021-04-21 The Board of Regents of The University of Texas System Interferon prodrug for the treatment of cancer
EA202090247A1 (en) 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. ANTIBODIES AGAINST CD166 AND THEIR APPLICATION
JP2020530554A (en) 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド Methods and Uses for Qualitative and / or Quantitative Analysis of Activating Antibody Properties
EP3668548A2 (en) 2017-08-17 2020-06-24 Nektar Therapeutics Immunotherapeutic tumor treatment method
MX2020002198A (en) 2017-08-30 2020-07-20 Cytomx Therapeutics Inc Activatable anti-cd166 antibodies and methods of use thereof.
PE20212205A1 (en) * 2017-09-08 2021-11-18 Maverick Therapeutics Inc RESTRICTED CONDITIONALLY ACTIVATED BINDING PROTEINS
CN111315773A (en) * 2017-09-08 2020-06-19 马弗里克治疗公司 Conditionally active binding moieties comprising an Fc region
JP7438106B2 (en) 2017-10-14 2024-02-26 シートムエックス セラピューティクス，インコーポレイテッド Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3706770A4 (en) 2017-11-07 2021-10-27 Nektar Therapeutics Immunotherapeutic combination for treating cancer
JP2021515599A (en) 2018-03-09 2021-06-24 アスクジーン・ファーマ・インコーポレイテッドＡｓｋＧｅｎｅ Ｐｈａｒｍａ， Ｉｎｃ． New cytokine prodrug
CU24554B1 (en) 2018-05-07 2021-11-04 Ct Inmunologia Molecular FUSION PROTEINS COMPOSED OF INTERLEUKIN 2 MUTEIN AND TYPE 1 INTERFERON
ES2955511T3 (en) * 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Activatable interleukin 2 polypeptides and methods of use thereof
JP2021524756A (en) 2018-05-14 2021-09-16 ウェアウルフ セラピューティクス， インコーポレイテッド Activateable cytokine polypeptides and how to use them
KR20210038548A (en) 2018-06-22 2021-04-07 큐진 인크. Cytokine-based bioactive drugs and methods of use thereof
JP2022502088A (en) 2018-09-27 2022-01-11 エクシリオ デベロップメント， インコーポレイテッド Masked cytokine polypeptide
KR20220020879A (en) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. New IL-15 prodrugs and how to use them
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. Il-2 cytokine prodrugs comprising a cleavable linker
US20220306714A1 (en) 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
JP2023520517A (en) 2020-04-01 2023-05-17 エクシリオ デベロップメント， インコーポレイテッド Masked IL-2 cytokines and their cleavage products
TW202204386A (en) 2020-04-01 2022-02-01 美商艾希利歐發展股份有限公司 Masked il-12 cytokines and their cleavage products
BR112022019789A2 (en) 2020-04-01 2022-11-16 Xilio Dev Inc IL-15 MASKED CYTOKINES, CLEAVAGE PRODUCTS, NUCLEIC ACID, VECTOR, HOST CELL, COMPOSITION, PHARMACEUTICAL COMPOSITION, KIT AND METHODS OF PRODUCING A MASKED IL-15 CYTOKINE AND TREATMENT OR PREVENTION OF CANCER

Also Published As

Publication number Publication date
KR20220023988A (en) 2022-03-03
US20210115102A1 (en) 2021-04-22
JP2022532217A (en) 2022-07-13
EP3969035A1 (en) 2022-03-23
US20230272028A1 (en) 2023-08-31
MX2021013766A (en) 2022-02-21
BR112021022666A2 (en) 2022-03-29
AU2020275877A1 (en) 2021-12-23
WO2020232305A1 (en) 2020-11-19
US20220220181A1 (en) 2022-07-14
CN114450022A (en) 2022-05-06
EP3969035A4 (en) 2023-06-21
US11739132B2 (en) 2023-08-29
IL287977A (en) 2022-01-01
CA3137512A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
IL287977A (en) Separation moieties and methods and use thereof
ZA202003999B (en) System and methods
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
GB2591554B (en) Composiitons and methods and uses relating thereto
IL284514A (en) Halo-allylamine compounds and use thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL283165A (en) Adenoviruses and methods for using adenoviruses
GB201903827D0 (en) New compounds and methods
GB201903832D0 (en) New compounds and methods
EP3677674C0 (en) Transaminase mutant and use thereof
GB201817362D0 (en) Circuitry and method
GB201802122D0 (en) Product and use
IL280369A (en) New myokines and uses thereof
EP4051270A4 (en) 4-amino-imidazoquinoline compounds and use thereof
GB201911133D0 (en) Materials and methods
GB201911127D0 (en) Materials and methods
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
GB2589437B (en) Circuitry and methods
IL287503A (en) Thiosemicarbazates and uses thereof
GB201902266D0 (en) New methods and uses
GB201812776D0 (en) New methods and uses
GB2580127B (en) Circuitry and method
IL278919A (en) Combinations comprising tropifexor and cenicriviroc
GB201911629D0 (en) Materials and methods
GB201911130D0 (en) MAterials and methods